|国家科技期刊平台
首页|期刊导航|中国医学创新|重组牛碱性成纤维细胞生长因子在白内障超声乳化术后的应用效果

重组牛碱性成纤维细胞生长因子在白内障超声乳化术后的应用效果OA

Application Effect of Recombinant Bovine Basic Fibrolast Growth Factor in Cataract Phacoemulsification Surgery

中文摘要英文摘要

目的:探讨左氧氟沙星、妥布霉素地塞米松滴眼液联合重组牛碱性成纤维细胞生长因子在白内障超声乳化术后的应用效果.方法:选取 2020 年 1 月—2022 年 12 月在吉安市第一人民医院五官科接受白内障超声乳化术的 80 例患者为研究对象,进行回顾性研究.根据治疗方式不同分为对照组和试验组,每组 40 例.对照组患者给予左氧氟沙星和妥布霉素地塞米松滴眼液,试验组给予左氧氟沙星、妥布霉素地塞米松滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液.通过干眼症状评分(SPEED)和角膜荧光素染色评分(FLS)评估患者治疗前后的眼部症状;通过对患者治疗前后血清中一氧化氮(NO)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和总抗氧化能力(TAC)的比较,分析其抗氧化指标;测定患者治疗前后白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α),比较血清炎症因子水平;并比较患者用药期间眼部刺激感、眼部疼痛感、眼部瘙痒感等不良反应情况.结果:试验组患者治疗后的SPEED和FLS评分均低于对照组,差异均有统计学意义(P<0.05),试验组患者治疗后NO水平比对照组低,SOD、CAT、TAC均比对照组高,并且血清炎症因子水平在治疗后均显著比对照组低,差异均有统计学意义(P<0.05),试验组患者用药期间的不良反应发生率比对照组低,差异有统计学意义(P<0.05).结论:左氧氟沙星、妥布霉素地塞米松滴眼液联合重组牛碱性成纤维细胞生长因子的使用有助于改善患者术后眼部状况,提高抗氧化指标,降低炎症因子水平和用药期间不良反应发生率,有较高的临床应用价值.

Objective:To explore the application effect of Levofloxacin,Tobramycin Dexamethasone Eye Drops combined with Recombinant Bovine Basic Fibrolast Growth Factor in patients after cataract phacoemulsification surgery.Method:A total of 80 patients who underwent cataract phacoemulsification surgery in the Department of Ophthalmology and Otorhinolaryngology of Ji'an City First People's Hospital from January 2020 to December 2022 were retrospectively studied.They were divided into a control group and an experimental group according to different treatment methods,with 40 patients in each group.The control group was treated with Levofloxacin and Tobramycin Dexamethasone Eye Drops,while the experimental group was treated with Levofloxacin,Tobramycin Dexamethasone Eye Drops combined with Recombinant Bovine Basic Fibrolast Growth Factor Eye Drops.The eye symptoms of the patients before and after treatment were evaluated using the symptom evaluation for eye dryness(SPEED)score and the fluorescein staining of the cornea(FLS)score.By comparing the levels of nitric oxide(NO),superoxide dismutase(SOD),catalase(CAT)and total antioxidant capacity(TAC)in the serum of patients before and after treatment,the antioxidant indicators were analyzed.Levels of interleukin-8(IL-8),IL-6 and tumor necrosis factor-α(TNF-α)were also determined to compare serum inflammatory factor levels.The incidence of adverse reactions such as irritation,pain and itching in the eyes during medication use was also compared.Result:The SPEED and FLS scores of the experimental group were significantly lower than those of the control group after treatment,the differences were statistically significant(P<0.05).After treatment,the NO level in the experimental group was lower compared to the control group,while SOD,CAT,and TAC levels were higher,serum inflammatory factors levels were also significantly lower in the experimental group after treatment compared to the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions during medication use in the experimental group was significantly lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:The use of Levofloxacin,Tobramycin Dexamethasone Eye Drops combined with Recombinant Bovine Basic Fibrolast Growth Factor can help improve the postoperative eye condition of the patients,enhance the antioxidant indicators,reduce the levels of inflammatory factors,and decrease the incidence of adverse reactions during medication use.It has significant clinical application value.

彭礼岚;吴宗;江莲香

吉安市第一人民医院五官科 江西 吉安 343000

左氧氟沙星妥布霉素地塞米松重组牛碱性成纤维细胞生长因子白内障超声乳化术

LevofloxacinTobramycin DexamethasoneRecombinant Bovine Basic Fibroblast Growth FactorCataract phacoemulsification surgery

《中国医学创新》 2024 (012)

35-39 / 5

10.3969/j.issn.1674-4985.2024.12.009

评论